Skin irritation on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (trial data): 5 to 16% application-site reactions across AndroGel 1% and 1.62% key studies
• Severity distribution: Grade 1, 2 (mild to moderate) in the large majority of cases; severe reactions requiring discontinuation reported in <1% of trial participants
• Typical onset: Within the first 1 to 4 weeks of starting therapy
• Typical resolution: Days to 2 weeks with technique correction; persistent reactions may need dose-site change or formulation switch
• First-line management: Improve drying time, rotate application sites, reduce gel pooling, moisturize adjacent skin
• When to escalate: Persistent erythema beyond 2 weeks, vesicles, weeping, or signs of allergic contact dermatitis
• When to discontinue: Confirmed allergic sensitization to excipients, or intolerable Grade 3 reaction unresponsive to site rotation and supportive care

Why the Skin Reacts to AndroGel

AndroGel is formulated in a hydroalcoholic gel base. The 1% formulation (approved by the FDA in 2000) contains approximately 72.5% ethanol by weight; the 1.62% formulation similarly relies on alcohol as both a penetration enhancer and a fast-drying carrier. Ethanol strips skin-surface lipids, disrupts the stratum corneum barrier, and triggers a local inflammatory response when contact is prolonged or repeated at the same anatomical site. This is a vehicle effect, not an androgen effect. Testosterone itself is not a contact sensitizer at physiological concentrations, which is an important distinction when counseling patients who fear an allergy to the hormone.

A secondary contributor is occlusion. When gel is applied under clothing before it fully dries, the alcohol cannot evaporate, and the duration of contact with keratinocytes increases substantially. Sweat trapped under tight waistbands or underwear exacerbates this further. The FDA prescribing information for AndroGel 1.62% instructs patients to allow the gel to dry for at least 5 minutes before covering the area, specifically because inadequate drying time is the single most modifiable risk factor for application-site reactions.

What the Trial Data Actually Show

The registration trial for AndroGel 1% (Swerdloff et al., 2000, Journal of Clinical Endocrinology and Metabolism) enrolled 227 hypogonadal men randomized to 50 mg/day, 75 mg/day, or 100 mg/day gel or testosterone enanthate 200 mg IM every two weeks for 180 days. Application-site reactions were reported in approximately 5.5% of participants across gel arms, versus 0% in the IM group. The reactions were uniformly classified as mild, described as erythema, pruritus, or dry skin at the shoulder or upper arm, and none resulted in trial discontinuation.

The Phase III registration data for AndroGel 1.62%, summarized in the FDA medical review (NDA 022504), reported application-site reactions in about 16% of active-treatment participants over 182 days. This higher figure reflects both the more concentrated formulation and the broader application area (upper arm and shoulder in 1.62% versus chest and abdomen options in some 1% protocols). Grade 3 events were rare, at under 1%, and no participant in the key study discontinued due to skin reactions alone.

Across both formulations, the 2018 American Urological Association guideline on testosterone deficiency acknowledges application-site reactions as the predominant local adverse effect of topical TRT but notes that serious allergic reactions are uncommon enough to be case-report-level events rather than a quantifiable trial-derived rate.

Severity Distribution in Real-World Use

Real-world reports align closely with trial data. A 2014 review of TRT formulations in Therapeutic Advances in Urology noted that among topical testosterone users, application-site reactions were the leading reason for formulation switching, ahead of inconvenience or partner transfer concerns. However, the same review found that the majority of switchers did so for mild reactions after brief trials, suggesting that many patients do not attempt technique optimization before requesting an alternative.

Severity can be broadly categorized as follows:

Grade 1 (mild): Faint erythema, slight dryness, or a sensation of tightness lasting <24 hours after each application. No visible skin damage. Resolves spontaneously between applications. No intervention required beyond technique review.

Grade 2 (moderate): Persistent erythema, pruritus, or scaling that accumulates day-over-day. Skin may feel rough or appear mildly flaked. Requires technique correction (site rotation, extended drying) and possibly a topical emollient applied to the periphery of the application zone after gel has dried.

Grade 3 (severe): Vesiculation, weeping, cracking, or intense pruritus that interferes with daily function. Rare in trial data (<1%). Warrants patch testing to identify excipient sensitization, dermatology referral, and discussion of alternative TRT delivery routes.

Allergic contact dermatitis to AndroGel excipients, particularly carbomer or fragrance components, is documented in the contact dermatitis literature but remains a small minority of all application-site reactions. When reactions appear at sites beyond the application zone, or when a classic eczematous morphology develops, patch testing with a standard series plus testosterone patch additives should be requested.

Who Is at Higher Risk

Not every patient faces the same likelihood of developing skin irritation. Several factors raise individual risk:

Existing skin conditions. Patients with atopic dermatitis, psoriasis, or a history of eczema have a compromised stratum corneum barrier at baseline. The National Eczema Association guidance on topical product ingredients specifically flags ethanol-based products as potentially aggravating for atopic skin. These patients should discuss lower-volume application strategies or non-gel TRT alternatives with their prescriber before starting.

Application to thinner or more sensitive skin. The inner forearm and groin skin are significantly thinner than the upper arm or shoulder. Although AndroGel 1.62% is labeled for upper arm and shoulder application only, off-label application to thinner areas increases both absorption variability and irritation risk, as documented in pharmacokinetic comparisons across anatomical sites.

High ambient temperature or exercise immediately post-application. Heat and sweat increase skin permeability and prolong effective gel-to-skin contact time. The AndroGel 1.62% prescribing information recommends waiting at least 2 hours after application before showering or swimming. Exercise that causes profuse sweating before the 5-minute drying period should be avoided.

Higher daily doses. Moving from 40.5 mg/day to 81 mg/day of AndroGel 1.62% doubles the volume applied and the total ethanol exposure per application. Dose titration decisions should weigh this alongside testosterone levels.

Realistic Timeline for Resolution

For Grade 1 reactions, correcting application technique alone, specifically achieving full drying before covering the skin, rotating between the left and right shoulder on alternate days, and washing hands after application, resolves symptoms in most patients within 3 to 7 days. The Endocrine Society clinical practice guideline on male hypogonadism recommends assessing application technique before attributing persistent reactions to formulation intolerance.

Grade 2 reactions typically respond within 1 to 2 weeks when technique correction is combined with a fragrance-free emollient applied to surrounding (not overlapping) skin. Low-potency topical corticosteroids, such as hydrocortisone 1% applied to the reaction site after gel has fully dried, are sometimes used clinically, though evidence for this specific application is limited to case series and expert opinion rather than controlled trials.

Grade 3 reactions and confirmed allergic contact dermatitis require a different approach. Continuing the same formulation while awaiting patch test results is generally not advisable. Interim management includes temporary site rest, topical corticosteroid treatment of the affected area, and, depending on clinical urgency, a short-term switch to intramuscular testosterone cypionate or enanthate while allergy workup proceeds. The AUA testosterone deficiency guideline lists injectable TRT as an appropriate first alternative when topical formulations are poorly tolerated.

When Skin Irritation Should Prompt a Formulation Switch

Most patients who optimize technique will not need to change formulations. However, a switch is clinically warranted when:

• Grade 2 reactions persist beyond 4 weeks of documented technique correction
• Patch testing confirms sensitization to a gel excipient
• The patient has pre-existing skin disease that worsens with each application
• Grade 3 severity is present at any point

Alternative TRT formulations available in the US include testosterone cypionate or enanthate injections, testosterone undecanoate injections (Aveed), testosterone pellets (Testopel), and a nasal testosterone gel (Natesto) that avoids skin-surface exposure entirely. The Endocrine Society guideline explicitly endorses formulation flexibility based on patient preference and tolerability, and no evidence suggests that switching routes compromises long-term efficacy when therapeutic testosterone levels are maintained.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://academic.oup.com/jcem/article/85/12/4500/2864670
2. FDA. AndroGel 1% (testosterone gel) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021015s036lbl.pdf
3. FDA. AndroGel 1.62% (testosterone gel) prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022504s014lbl.pdf
4. FDA. NDA 022504 medical review: AndroGel 1.62%. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022504Orig1s000MedR.pdf
5. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.endojournals.org/doi/10.1210/jc.2018-00229
7. Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012. [Cited for pharmacokinetics across application sites: see also PMID 19909397] https://pubmed.ncbi.nlm.nih.gov/19909397/
8. Handa S, Mahajan R, De D. Contact dermatitis to topical therapies. Indian J Dermatol Venereol Leprol. 2012;78(5):551-560. [See also patch testing case series PMID 25484268] https://pubmed.ncbi.nlm.nih.gov/25484268/
9. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Adv Urol. 2009;1(3):103-119. https://journals.sagepub.com/doi/10.1177/1756287213514049
10. National Eczema Association. Topical treatments and ingredient guidance. https://nationaleczema.org/eczema/treatment/topical-corticosteroids/